Physician
Saratoga Schenectady Gastroenterology Associates, PC
Saratoga Schenectady Gastroenterology Associates, PC was paid $1.58M by Medicaid between Jan 2018 and Nov 2024, across 15 billing codes. Its largest line is J3380, Injection, vedolizumab, intravenous, 1 mg — 52% of everything it billed.
33Billing provider infoSARATOGA SCHENECTADY GASTROENTEROLOGY ASSOCIATES, PC
BURNT HILLS, NY 12027
BURNT HILLS, NY 12027
33aNPI1093724767assigned 08/05/2006
33bProvider typeGastroenterology Physician
28Total paid$1.58M
24GClaims7,337
24DCodes billed15
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Gastroenterology Physician providers in New York
Rank by total paid#37 of 656
Median peer was paid$12K
This provider vs. median130×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 257 | $26K | |
| 2019 | 426 | $41K | |
| 2020 | 828 | $195K | |
| 2021 | 1,120 | $265K | |
| 2022 | 1,472 | $717K | |
| 2023 | 1,734 | $182K | |
| 2024incomplete | 1,500 | $151K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 52% | 136 | 132 | $823K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 14% | 1,816 | 1,749 | $215K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.3% | 1,671 | 1,651 | $147K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 6.7% | 956 | 935 | $106K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.3% | 779 | 779 | $99K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 2.7% | 13 | 13 | $43K |
| 88342 | 2.5% | 631 | 626 | $39K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 541 | 535 | $37K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.6% | 274 | 274 | $25K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 128 | 128 | $13K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 92 | 90 | $11K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 71 | 71 | $9K |
3 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFRANCISCO, JOHN (MANAGING PARTNER)